The OSAKA Trial: A Randomized, Controlled Trial Comparing Tacrolimus QD and BD in Kidney Transplantation: Erratum
ثبت نشده
چکیده
In the November 27, 2013 issue of Transplantation in the article by Albano and Banas et al, ‘‘OSAKATrial: A Randomized, Controlled Trial Comparing Tacrolimus QD and BD in Kidney Transplantation’’, there was an error in the reporting of the confidence intervals for the composite endpoint (the upper values are reported as negative instead of positive values). The incidence of graft loss (overall) and the incidence of delayed graft function (Arm 4) were also reported incorrectly. The corrected passages appear below with the revised information in bold font. These data adjustments do not affect the clinical conclusions that were presented and discussed in this publication.
منابع مشابه
OSAKA Trial: A Randomized, Controlled Trial Comparing Tacrolimus QD and BD in Kidney Transplantation
BACKGROUND The once-daily (QD), prolonged-release formulation of tacrolimus has been shown to improve adherence versus twice-daily (BD) tacrolimus. Treatment nonadherence in transplant recipients has been associated with poor graft outcomes. METHODS This open-label, parallel-group study randomized adults with end-stage renal disease undergoing primary kidney transplantation or retransplantati...
متن کاملCombination therapy with everolimus and tacrolimus in kidney transplantation recipients: A systematic review
Background and aims: Immunosuppressive regimens are a key component for successful kidney transplantation. This systematic review aimed to assess the efficacy and safety of combination therapy of everolimus with tacrolimus in kidney transplantation recipients. Methods: Results were limited to English-language articles. Trials where recipients received ano...
متن کاملComparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
BACKGROUND A prolonged-release formulation of tacrolimus (Tacrolimus QD) was developed to allow once-daily dosing and to have similar safety and efficacy profiles to twice-daily tacrolimus (Tacrolimus BID). This study compared the pharmacokinetics (PK) and renal pathology by protocol biopsy in de novo living kidney transplant recipients treated with either low-dose Tacrolimus QD or Tacrolimus B...
متن کاملThe efficacy of camel milk and Tarangabin (manna of Alhagi maurorum( combination therapy on glomerular filtration rate in patients with chronic kidney disease: A randomized controlled trial
Objective: This study was designed to investigate the effect of camel milk and Tarangabin (manna of Alhagi maurorum) combination therapy in addition to conventional treatments in patients with chronic kidney disease (CKD). Material and Methods: Forty-four patients of 15 to 70 years old, with CKD due to hypertension or diabetes, and estimated glomerular filtration rate (eGFR) of 15–60 ml...
متن کاملTacrolimus in renal transplantation.
The early studies with tacrolimus. from 1989 through 1991, included a pilot series, a small randomized trial, and a larger nonrandomized group. I.3.4 When the outcome of these patients was compared with that in a roughly concurrent (although somewhat less challenging) group of cyclosporine (CyA)-treated patients, equivalent patient and graft survival rates were seen. However, improved secondary...
متن کامل